- Home
- SLS vs BCSF Comparison
SLS vs BCSF Comparison
Compare SLS & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLS | BCSF |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 838.7M |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLS | BCSF |
|---|---|---|
| Price | $13.41 | $11.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 6.4M | 388.8K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.61% |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $110.98 | N/A |
| P/E Ratio | ★ N/A | $44.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $11.82 |
| 52 Week High | $15.88 | $15.79 |
Technical Indicators
Market Signals| Indicator | SLS | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 36.34 |
| Support Level | $11.43 | $11.90 |
| Resistance Level | $15.77 | $13.74 |
| Average True Range (ATR) | 1.19 | 0.26 |
| MACD | 0.14 | -0.05 |
| Stochastic Oscillator | 62.22 | 6.45 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.